PFG Private Wealth Management’s Adaptive Biotechnologies ADPT Stock Holding History

PFG Private Wealth Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10	Closed	–	–	305
2021 Q3	$0	Buy	+10	New	+$362	﹤0.01%	304

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PFG Private Wealth Management's ADPT Position: Q4 2021 in Review

PFG Private Wealth Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2021, closing a stake of 10 shares.

PFG Private Wealth Management first reported a position in ADPT in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 214 funds tracked by Wall St. Rank hold ADPT as of Q4 2021.

PFG Private Wealth Management reported no remaining Adaptive Biotechnologies position as of Q4 2021 after selling out during the quarter.
PFG Private Wealth Management sold 10 Adaptive Biotechnologies shares in Q4 2021.
PFG Private Wealth Management first reported a position in Adaptive Biotechnologies in Q3 2021 and held it in 1 quarter.
PFG Private Wealth Management's Adaptive Biotechnologies position peaked at $0 in Q3 2021.
214 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2021.

Based on PFG Private Wealth Management's 13F filing for Q4 2021, filed 27 Jan 2022.